US Menopause Hormone Therapy Guidance Raises Questions for Breast Cancer Survivors and Nutrient Deficiencies

The U.S. Food and Drug Administration removed black‑box warnings on menopausal hormone therapy in November 2025, creating a gray zone about who should receive the treatment. While hormone therapy can relieve hot flashes and support heart and bone health, the 1990s Women’s Health Initiative study linked it to an increased risk of breast cancer, prompting long‑standing caution among clinicians.

New guidance urges clinicians to tailor hormone therapy to individual patients, especially breast cancer survivors who historically have avoided it despite potential quality‑of‑life benefits. Experts note that not all menopausal symptoms—fatigue, memory lapses, muscle weakness—are solely due to declining estrogen; nutritional deficiencies can also play a role. Gynecologist Ana Paula Fabricio recommends evaluating lab tests for vitamin and mineral gaps before attributing every complaint to hormonal change.

The evolving discussion reflects broader efforts to balance symptom relief with safety, emphasizing personalized assessment for the roughly one‑in‑eight U.S. women who will face a breast cancer diagnosis in their lifetime.